| Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer NH Mumin, N Drobnitzky, A Patel, LM Lourenco, FF Cahill, Y Jiang, ... BMC cancer 19, 1-14, 2019 | 38 | 2019 |
| Conducting multiple mini-interviews in the midst of COVID-19 pandemic KY Kok, L Chen, FI Idris, NH Mumin, H Ghani, IN Zulkipli, MA Lim Medical Education Online 26 (1), 1891610, 2021 | 21 | 2021 |
| Phytochemicals with anti 5-alpha-reductase activity: a prospective for prostate cancer treatment A Azizi, NH Mumin, N Shafqat F1000Research 10, 2021 | 13 | 2021 |
| Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment [version 1; peer A Azizi, NH Mumin, N Shafqat | | 2021 |
| Abstract B30: Novel targets for combination therapy in EGFR mutated NSCLC N Drobnitzky, A Patel, A Mumin, F Cahill, LM Lourenco, S Olyha, ... Molecular Cancer Therapeutics 16 (10_Supplement), B30-B30, 2017 | | 2017 |
| Acquired resistance to HSP90 inhibition in triple-negative breast cancer D Mumin University of Oxford, 2016 | | 2016 |
| Abstract B88: Mechanisms of resistance to the Hsp90 inhibitor ganetespib in triple negative breast cancer NH Mumin, S Bokobza, F Cahill, N Drobnitzky, Y Jiang, L Madia Lourenco, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), B88-B88, 2015 | | 2015 |
| Abstract C114: The role of LKB1 and TP53 mutation status in determining sensitivity of non-small cell lung cancer cells to the metabolic inhibitors; metformin, phenformin and 2-DG FF Cahill, S Bokobza, A Devery, N Drobnitzky, Y Jiang, L Madia Lourenco, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), C114-C114, 2015 | | 2015 |
| Commonwealth Science Conference 2017 Posters MM Rahman, JA Howell, DIM Macdonald | | |
